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Abstract
Introduction Patients receiving statin therapy for dyslip-
idaemia often require treatment with an additional agent to
control triglyceride levels. Options for add-on therapy
include fibrates and omega-3 fatty acids. This case series
describes the effects of switching add-on therapy from
fenofibrate to icosapent ethyl (the ethyl ester of the omega-
3 fatty acid, eicosapentaenoic acid) on patient lipid profiles.
Methods This was a retrospective analysis of patient
records from a private medical practice in western New
York. Statin-treated patients with dyslipidaemia who had
been treated with fenofibrate and later switched to icos-
apent ethyl were selected for analysis. Lipid profiles before
and after the switch to icosapent ethyl were compared.
Results The records of five patients were analysed. All
patients had hypertension and were overweight, male, and
at high cardiovascular risk. After the switch to icosapent
ethyl (treatment duration 3.9–5.8 months), triglyceride
levels decreased in four patients, and low-density
lipoprotein cholesterol, non-high-density lipoprotein
cholesterol, and total cholesterol levels decreased in all
patients. High-density lipoprotein levels increased in four
patients. Icosapent ethyl was well tolerated.
Conclusions Switching from fenofibrate to icosapent
ethyl as add-on to a statin therapy due to clinical need may
provide an option for patients to maintain or improve lipid
parameters.
Introduction
Treatment of dyslipidaemia with statins is effective for
lowering low-density lipoprotein cholesterol (LDL-C) levels
and can improve levels of other lipids [1, 2]. However,
triglyceride (TG) levels in statin-treated patients may remain
uncontrolled, leaving patients at residual risk for cardio-
vascular events [3]. Fibrates, niacin, and prescription omega-
3 fatty acids are indicated to reduceTG levels in patientswith
severe (C500 mg/dL) hypertriglyceridaemia, and may be
options as add-on therapy to statins in patients with persis-
tently elevated TG levels [4]. Fibrates, available since the
1990s, effectively lower TG levels, but safety issues, such as
the potential for myopathy and unwanted effects on LDL-C,
may warrant reassessment of therapeutic use, particularly in
some patients receiving statin therapy [5–8].
In 2012, icosapent ethyl (Vascepa; Amarin Pharma
Inc., Bedminster, NJ), a high-purity prescription formu-
lation containing the ethyl ester of eicosapentaenoic acid
(EPA), was approved by the US FDA. Icosapent ethyl is
indicated as an adjunct to diet to reduce TG levels in adult
patients with severe (C500 mg/dL) hypertriglyceridaemia
[9]. EPA is the sole active ingredient in icosapent ethyl
[9] and has been shown to reduce TG, non-high-density
lipoprotein cholesterol (non-HDL-C), and total cholesterol
(TC) levels without raising LDL-C levels in patients with
very high TG levels (C500 and B2000 mg/dL), as well as
in statin-treated patients with residually high TG levels
(C200 and\500 mg/dL) [10, 11]. Icosapent ethyl has
been found to be safe and generally well tolerated, with a
safety profile similar to that of placebo [9–11]. In double-
blind studies, arthralgia was the only adverse reaction
reported to occur in[2 % of patients treated with icos-
apent ethyl and at an incidence rate greater than that for
placebo [9].
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Because of the robust safety and efficacy profile of
icosapent ethyl, patients receiving fibrate therapy were
gradually switched to treatment with icosapent ethyl in a
private medical practice in western New York, a geo-
graphical area known for its high risk of heart disease and
stroke [12]. The objective of this analysis was to retro-
spectively assess the lipid profile effects of switching sta-
tin-treated patients from fibrate therapy to icosapent ethyl.
Methods
Study design
This retrospective chart review was carried out at a single
private medical practice with offices located in Franklin-
ville, Tonawanda, Lancaster, and Niagara Falls, NY.
Patient records were eligible for review if the patients had
TG levels C500 mg/dL at some point in their medical
history and if they were receiving stable fibrate therapy in
addition to stable statin therapy and were switched from
fibrate therapy to icosapent ethyl while continuing with
stable statin therapy. Patients were required to have been
treated with icosapent ethyl plus a statin for[2 months,
have available lipid measurements, and have been clini-
cally stable for the period encompassing when the lipid
measurements were made while on fibrate therapy and
while on icosapent ethyl. Patients were excluded if they
had any gaps in treatment, missing lipid measurements,
known non-compliance, or any changes in clinical condi-
tion or medications that could affect lipid parameters.
Written informed consent was received from all patients
included in this case series.
Assessments
Lipid parameters were assessed a minimum of 2 months
after the initiation of fenofibrate therapy and a minimum of
2 months after the switch to icosapent ethyl. Blood samples
for lipid analysis were collected from patients after an
overnight fast and analysed by local laboratories as speci-
fied by patient insurance. Parameters measured included
TG, LDL-C, HDL-C, TC, and non-HDL-C levels.
Body mass index was calculated as weight in kilograms
divided by height in metres squared. LDL-C levels were
calculated using the Friedewald formula [i.e. LDL-C = TC
minus HDL-C minus (TG/5)] in some instances (note, the
Friedewald formula should not be used when TG levels
are[400 mg/dL) [13]. Non-HDL-C levels were calculated
as TC minus HDL-C [14]. Percentage changes in individ-
ual patient lipid parameters from before and after the
switch from add-on fibrate therapy to treatment with
icosapent ethyl were calculated.
Results
Patients and treatments
The medical records of five patients (aged 58–66 years)
met the inclusion criteria and were analysed (Table 1). All
patients were overweight men with hypertension and high
cardiovascular risk. One patient had coronary heart disease
and chronic kidney disease.
All patients were on stable doses of moderate-intensity
statins, including lovastatin, extended-release fluvastatin,
or atorvastatin therapy and subsequently initiated fibrate
therapy between August 2007 and June 2010 (before the
approval of icosapent ethyl). Fibrate therapy consisted of
fenofibrate tablets 145 mg once daily (Tricor; AbbVie
Inc., North Chicago, IL) in two patients, and fenofibrate
capsules 150 mg once daily (Lipofen; Kowa Pharma-
ceuticals America, Inc., Montgomery, AL) in the remain-
ing three patients.
Add-on therapy was switched from fibrate therapy to
icosapent ethyl between March and September 2014. After
the switch, all patients received two capsules of icosapent
ethyl twice daily, for a total dosage of 4 g/day in addition
to their stable statin regimen. All patients had been treated
with icosapent ethyl ? statin therapy for C3.9 months
(range 3.9–5.8 months) before lipid measurements.
Because of comorbidities, patients were also receiving
other medications (antihypertensive agents: amlodipine/
olmesartan, atenolol, nebivolol, olmesartan, quinapril,
verapamil; others: albuterol, aspirin, azelastine, cetirizine,
levothyroxine, mometasone furoate, montelukast sodium,
omeprazole).
Lipid parameters
TG levels ranged from 91 to 278 mg/dL during the period
when patients were receiving fenofibrate ? statin and from
81 to 190 mg/dL when they were receiving icosapent
ethyl ? statin (Table 1). Four patients experienced a
decrease in TG level after switching from fenofibrate to
icosapent ethyl, with decreases ranging from 8 to 53 %
(Table 1). The remaining patient had an increase of 4 % in
TG level, from 182 mg/dL while on fenofibrate ? statin to
190 mg/dL while on icosapent ethyl ? statin (Table 1).
While patients were receiving fenofibrate ? statin, their
LDL-C levels ranged from 55 to 170 mg/dL (Table 1).
After the switch to icosapent ethyl, LDL-C levels
decreased in all patients, with a maximum decrease of
44 % in one patient (Table 1).
Reductions in non-HDL-C levels, ranging from 3 to
39 %, were observed in all patients following the switch
from fenofibrate ? statin to icosapent ethyl ? statin
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Table 1 Characteristics and lipid levels of statin-treated patients switched from fibrate therapy to icosapent ethyl
Parameter Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Patient characteristics
Age (years)a 58 63 61 64 66
Body mass index (kg/m2) 26 28 30 33 28


















Treatment dosage and duration




Fenofibrate daily dosage (mg) 145 145 150 150 150
Time on fibrate ? statin (months)b 17.7 17.9 29.4 29.0 4.7
Time on icosapent ethyl ? statin
(months)c
5.0 5.8 4.8 3.9 3.9
Triglyceride levels (mg/dL)
Before statin 545 564 509 522 592
Statin alone 245 279 271 300 217
Fibrate ? statin 278 167 182 123 91
Icosapent ethyl ? statin 130 81 190 107 84
% changed -53.2 -51.5 ?4.4 -13.0 -7.7
Low-density lipoprotein cholesterol levels (mg/dL)e
Before statin 104 188 NR NR 189
Statin alone 96 126 84 180 88f
Fibrate ? statin 55 170 121 151 115
Icosapent ethyl ? statin 54 96f 105f 135f 96
% changed -1.8 -43.5 -13.2 -10.6 -16.5
Non-HDL-C levels (mg/dL)f
Before statin 202 189 212 228 NR
Statin alone 153 137 138 200 131
Fibrate ? statin 105 184 148 175 131
Icosapent ethyl ? statin 77 112 143 155 127
% changed -26.7 -39.1 -3.4 -11.4 -3.1
Total cholesterol levels (mg/dL)
Before statin 232 235 235 NR 272
Statin alone 188 185 168 243 184
Fibrate ? statin 136 231 177 211 178
Icosapent ethyl ? statin 112 160 172 201 175
% changed -17.7 -30.7 -2.8 -4.7 -1.7
HDL-C levels (mg/dL)
Before statin 30 46 23 41 52
Statin alone 35 48 30 43 53
Fibrate ? statin 31 47 29 36 47
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(Table 1). TC levels decreased in all patients (range
2–31 %) following the switch from fenofibrate ? statin to
icosapent ethyl ? statin (Table 1). An increase or no
change in HDL-C level was observed in all patients (range
0–28 %).
Safety
The switch from fenofibrate ? statin to icosapent
ethyl ? statin was well tolerated by all patients, with no
adverse effects reported. All patients are currently contin-
uing on this regimen. No changes in arthritis or arthralgia
were observed in one patient who had these conditions,
which were pre-existing to omega-3 fatty acid therapy.
Discussion
In this real-world retrospective analysis of high-risk
patients receiving statin therapy, patient medical records
were examined to evaluate the potential lipid effects of
switching from add-on fibrate therapy to the prescription
omega-3 fatty acid therapy icosapent ethyl while continu-
ing stable statin therapy. After switching from fenofibrate
to icosapent ethyl, lipid control was maintained or
improved, with all patients experiencing improvements in
atherogenic lipid parameters, including reductions in TC,
LDL-C, and non-HDL-C levels, and all but one patient
experienced a reduction in TG levels. The slight 4 %
increase in TG levels in one patient (from 182 to 190 mg/
dL) was not considered to be clinically significant; it is not
known what factors could have resulted in this increase, but
this may have been due to variability in laboratory mea-
surements or changes in patient diet, exercise, or medica-
tion adherence that were not reported during the office
visit.
Historically, fibrate and niacin products have been used
as adjunctive therapy to statins, with fibrates being more
commonly prescribed for high TG levels. This is reflected
in this case series, wherein TG levels improved in four of
the five patients when fenofibrate was added to statin
treatment. Nonetheless, potential safety concerns have
been recognized with the use of fibrates or niacin in
combination with statins. Several statin labels mention that
use in combination with fibrates or lipid-lowering doses of
niacin may increase the risk of adverse skeletal muscle
effects; however, in large outcomes trials, these events
were not very common with fibrates [15–19]. Some statin
labels specifically recommend avoiding concomitant ther-
apy with gemfibrozil and/or note an increased risk of
adverse skeletal muscle effects with gemfibrozil [16, 17,
20]. Fibrates also may increase levels of serum transami-
nases and serum creatinine, the former in combination with
statins [5, 6]. Importantly, fibrates may be associated with
increases in LDL-C levels, especially in patients with very
high TG levels, or attenuation of statin-induced reductions
in LDL-C levels [1, 7, 8, 21–27]. While the exact mecha-
nism of this increase in LDL-C levels is unknown, it may
in part be due to an increase in plasma PCSK9 levels
resulting from fibrate therapy [28–30]. With niacins,
flushing is a common tolerability concern, and other
potential adverse effects may include increased serum
glucose and hepatotoxicity or myopathy, especially when
co-administered with a statin [31].
A meta-analysis of 19 randomized studies found that
fibrate use was not associated with a reduced risk of all-
cause or coronary heart disease mortality or stroke; these
findings held true for the subset of studies in which fibrates
were used in combination with statins, and, in this subset,
fibrate therapy also did not reduce the risk of non-fatal
myocardial infarction [32]. Supporting this, a retrospective
analysis of patients with type 2 diabetes who were
Table 1 continued
Parameter Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Icosapent ethyl ? statin 35 48 29 46 48
% changed ?12.9 ?2.1 0.0 ?27.8 ?2.1
BPH benign prostatic hypertrophy, CHD coronary heart disease, CKD chronic kidney disease, ER extended release, GORD gastro-oesophageal
reflux disease, HDL-C high-density lipoprotein cholesterol, NR not reported
a Age at time of measurement while on icosapent ethyl
b Time from addition of fenofibrate to statin to when laboratory measurements were taken after initiation of fenofibrate
c Time from switch from fenofibrate ? statin to icosapent ethyl ? statin to when laboratory measurements were taken after icosapent ethyl was
initiated
d Percentage changes in lipid levels from when patient was on fibrate therapy to when on icosapent ethyl
e Values were measured directly unless otherwise noted
f Value is calculated based on other information available (see ‘‘Methods’’ section)
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receiving statins alone or in combination with fibrate
therapy showed that the use of combination therapy did not
reduce the incidence of cardiovascular disease compared
with the use of statins alone [33]. Notably, in April 2015,
the US FDA removed the indication for use of fenofibric
acid delayed-release capsules (Trilipix; AbbVie Inc.) and
niacin extended-release tablets (Niaspan; AbbVie Inc.) in
combination with statins from the product labels [6, 31,
34]. Thus, other options are needed for add-on therapy with
statins. The product label’s ‘limitations of use’ notes that
fenofibrate was not shown to reduce coronary heart disease
morbidity and mortality in patients with type 2 diabetes.
However, hypothesis-generating data from large cardio-
vascular outcomes trials suggest that patients with diabetes
and atherogenic dyslipidaemia characterized by high TG
and low HDL-C levels may benefit from treatment with
fenofibrate [18, 19]. This is yet to be proven in a large,
prospective, randomized, placebo-controlled trial.
Prescription omega-3 fatty acid products first became
commercially available in the USA in 2005 (Lovaza;
GlaxoSmithKline, Research Triangle Park, NC [35]) and
contained a combination of both EPA and docosahexaenoic
acid (DHA); additional EPA ? DHA products were
recently approved in 2014 (Omtryg; Trygg Pharma Inc.,
Arlington, VA [36], and Epanova; AstraZeneca Pharma-
ceuticals, Wilmington, DE [37]). Although these agents are
also effective in lowering TG levels, their prescribing
information warns that they may raise LDL-C levels [35–
37]. In pivotal clinical studies of patients with TG
levels C500 mg/dL, products that contain both EPA and
DHA were found to increase LDL-C levels by &15 to
49 % versus placebo [35–37]. Meta-analyses and system-
atic reviews have found that EPA and DHA have differ-
ential effects on LDL-C, wherein DHA may significantly
increase LDL-C levels while EPA may significantly
decrease or have a neutral effect on LDL-C levels [38, 39].
Thus, omega-3 fatty acid products containing DHA may
not be an optimal choice for patients with dyslipidaemia, as
they may have unwanted effects on LDL-C. As noted
earlier, icosapent ethyl, a high-purity form of EPA, does
not raise LDL-C levels in patients with very high TG levels
[9, 10]. Furthermore, in statin-treated patients with high TG
(C200 and\500 mg/dL) and well-controlled LDL-C
(\100 mg/dL) levels, icosapent ethyl 4 g/day was found to
significantly reduce LDL-C levels by 6 % versus placebo
(p = 0.007) [11]. In the current analysis of statin-treated
patients, LDL-C level decreases of 2–44 % were observed
in all patients following the switch from fenofibrate to
icosapent ethyl. In other retrospective chart analyses and
case reports, switching from prescription omega-3 fatty
acid products containing EPA ? DHA to icosapent ethyl
also resulted in decreases in TG and LDL-C levels, as was
observed in this analysis of patients switched from
fenofibrate therapy to treatment with icosapent ethyl [40–
45].
In addition to TG-lowering effects, omega-3 fatty acids
have other reported beneficial cardiovascular effects on
inflammation, blood pressure, thrombosis, and arrhythmia
[46]. Furthermore, EPA alone or in combination with a
statin may exert pleiotropic beneficial effects in multiple
steps of atherosclerosis, including antioxidant effects [47,
48]; endothelial function [49, 50]; effects on macrophages,
monocytes, and foam cells [51–53]; inflammation [54, 55];
plaque progression, formation, and vulnerability [52, 53,
56–59]; and thrombus formation [60, 61]. Given that
omega-3 fatty acid products containing DHA may raise
LDL-C levels and are not considered to be therapeutically
equivalent to icosapent ethyl, per FDA therapeutic equiv-
alence codes, they should not be substituted for prescrip-
tion icosapent ethyl [62]. It is worth noting that while many
non-prescription omega-3 fatty acid products are available
in the USA, these are dietary supplements, not over-the-
counter medications. Dietary supplements are not required
to prove or demonstrate safety or efficacy before marketing
[63–65], and have been found to have highly variable
product quality, purity, and EPA and DHA content within
and between brands [66–69]. Dietary supplements may
require a high pill burden to achieve prescription-strength
therapeutic doses [70, 71], and they also may contain
cholesterol, saturated fats [72, 73], contaminants such as
polychlorinated biphenyl [69], and oxidation products [67,
74]. Given these considerations, it may be important to
advise patients not to substitute omega-3 fatty acid dietary
supplements for prescription icosapent ethyl.
While no adverse effects occurred in the patients in this
assessment, safety and tolerability concerns regarding
fibrate and niacin products, as noted earlier, have informed
the switching of patients to safer, more tolerable options in
my practice. In three patients, LDL-C levels were higher
with fenofibrate ? statin (170, 121, and 115 mg/dL,
respectively) than on a statin alone (126, 84, and 88 mg/
dL); an attenuation of LDL-C control after addition of
fenofibrate to moderate- or high-intensity statins in patients
with dyslipidaemia has been described in the literature [8,
21, 27]. After the switch from fenofibrate ? statin to
icosapent ethyl ? statin, LDL-C levels decreased to 96,
105, and 96 mg/dL, respectively. As noted, omega-3 fatty
acid products containing DHA may potentially raise LDL-
C levels and have been associated with gastrointestinal
concerns, such as eructation, dyspepsia, taste perversion,
diarrhoea, nausea, abdominal pain or discomfort, and
constipation, which may cause tolerability issues [35–37].
Thus, icosapent ethyl represents a TG-lowering option with
fewer safety, tolerability, and efficacy concerns than other
available choices. When combining an additional lipid-
lowering agent with a statin, icosapent ethyl may offer
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greater flexibility in adjusting or increasing statin doses
than fenofibrate, given the potential safety issues and
effects on LDL-C of fibrate agents.
As to whether addition of icosapent ethyl to statin
therapy reduces cardiovascular risk, in the Japan EPA
Lipid Intervention Study (JELIS) of 18,645 patients with
hypercholesterolaemia, the ethyl ester of EPA, when added
to statin therapy, significantly reduced the risk of a major
coronary event by 19 % compared with statin alone (haz-
ard ratio 0.81; 95 % confidence interval 0.69–0.95;
p = 0.011) [75]. While the dosage of EPA in the JELIS
study was 1.8 g/day, the plasma levels achieved in JELIS
(169 lg/mL) were similar to those achieved with icosapent
ethyl 4 g/day (183 lg/mL) in statin-treated patients with
TG levels C200 and\500 mg/dL [75, 76]. The ongoing,
phase III, placebo-controlled Reduction of Cardiovascular
Events with EPA-Intervention Trial (REDUCE-IT; Clini-
calTrials.gov identifier NCT01492361) is investigating
whether icosapent ethyl 4 g/day in combination with statin
therapy is more effective than statin alone in improving
long-term cardiovascular outcomes in high-risk patients
with hypertriglyceridaemia [77].
Based on clinical decisions or due to the recent removal
of the indication for fenofibric acid use in combination with
statin therapy from the product label (and the expectation
of potentially similar revisions to the labels of generic
products), clinicians may wish to consider a different statin
add-on therapy for control of TGs and other lipids. The
present exploratory analysis may be of interest for those
wishing to identify other options for such patients.
The limitations of this case series include its small
sample size, retrospective design, and patient heterogeneity
regarding concomitant medications and underlying medical
conditions. In real-world settings such as this, other limi-
tations include lack of verification of patient compliance
with fasting before lipid assessments, adherence to con-
comitant medications, and possible effects of changes in
diet and exercise that were not reported to the physician.
Larger, prospective studies are needed to confirm these
hypothesis-generating findings.
Conclusion
Switching statin add-on therapy from fenofibrate to icos-
apent ethyl maintained or improved the lipid profile and
was well tolerated with no adverse reactions in a series of
patients with hypertension and high cardiovascular risk.
Important differences between icosapent ethyl and other
add-on therapy options include its good safety and tolera-
bility profile and the fact that it does not increase LDL-C
levels, as supported by clinical studies and the icosapent
ethyl product label.
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